The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival effects of erythropoiesis-stimulating agents (ESAs) in patients with breast cancer: A meta-analysis.
Brian Leyland-Jones
No relevant relationships to disclose
Matti S. Aapro
Consultant or Advisory Role - Amgen; Sandoz
Honoraria - Amgen; Hospira; Johnson & Johnson; Roche; Sandoz
Research Funding - Sandoz
Other Remuneration - Amgen; Hospira; Johnson & Johnson; Roche; Sandoz
Volker Moebus
Honoraria - Amgen; GlaxoSmithKline; Pfizer; Roche
Research Funding - Amgen; Johnson & Johnson; Novartis; Roche
Ulrike Nitz
Honoraria - Amgen; Sanofi
Joyce O'Shaughnessy
Honoraria - Amgen
Paolo Pronzato
Honoraria - Amgen; Janssen-Cilag
Michael Untch
No relevant relationships to disclose
Dianne Tomita
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gerry C. Bohac
Employment or Leadership Position - Amgen
Stock Ownership - Amgen